AlphAIAlphAI — Financial news for AI agents
minichart.com.sgOCT 283 min read$LH

Labcorp Q3 Revenue Rises 6.9% to $3.81B, Adjusted EPS Up 14.5%, Guidance Raised

Labcorp Holdings (NYSE: LH) reported Q3 2026 revenue of $3.81B, up 6.9% YoY, and raised full-year guidance. Adjusted EPS rose 14.5% to $4.78. Diagnostics and Biopharma segments showed growth, with margins expanding. The company announced acquisitions and declared a $0.72 dividend.

Original reporting
minichart.com.sg
Published Oct 28, 2026, 2:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 3:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Labcorp Q3 Revenue Rises 6.9% to $3.81B, Adjusted EPS Up 14.5%, Guidance Raised — source image
Source · minichart.com.sg
Decision brief

The 30-second read

$LHBullishHigh
01

Why it matters

The earnings beat and guidance lift are likely to drive short‑term buying interest, while the pending acquisitions introduce execution risk.

02

Market read

A large‑cap healthcare stock with fresh earnings beat and raised guidance; immediate relevance for traders focused on earnings momentum.

03

What to watch

Regulatory approvals for pending acquisitions remain uncertain and could dampen future earnings.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Labcorp disclosed its Q3 2026 results and updated full‑year guidance, including details on segment performance and recent M&A activity.

Company-level read

Ticker impact

$LHBullishHigh confidence
Context

Labcorp reported Q3 revenue up 6.9% to $3.81B and raised full‑year 2026 revenue and EPS guidance.

Expected impact

likely upward pressure as investors price in higher revenue and EPS expectations

Evidence & confidence

The company beat prior guidance and lifted its 2026 outlook, a material catalyst for the stock.

Market effects

Sector

Improves outlook for the broader diagnostics and clinical laboratory sector.

Regional

Positive for US healthcare stocks, especially other large lab service providers.

Global

Limited to healthcare investors; no direct global macro effect.

Counterpoint

What could challenge this read

If integration costs from recent acquisitions exceed expectations, the guidance raise could be premature.

Key entities

  • company
    Labcorp Holdings Inc.

    US‑listed diagnostics and drug development services provider.

  • acquisition target
    MLM Medical Labs

    Recent acquisition announced in the quarter.

Read at source← All news

StoryLabcorp posts Q3 2026 revenue and adjusted EPS growth and lifts full‑year guidance

Also covered by

5 outlets

Related articles

OCT 28
$LHHighAI 9/10

Labcorp adds more diagnostic services

Labcorp announced acquisitions totaling over $1 billion, including BioReference Health for up to $872 million and Myriad Genetics' Prenatal Health business for $210 million. The deals are expected to add $410 million in first-year revenue. Labcorp aims to expand diagnostic services, while Opko Health will focus on biopharmaceuticals.

thetimesnews.com2 min
OCT 28
$LHMedAI 8/10

Labcorp Boosts FY26 Outlook - Update

Labcorp (LH) raised its FY26 adjusted earnings guidance to $18.30-$18.70 per share and revenue to $14.779-$14.887 billion, up from prior estimates. The company also declared a $0.72 quarterly dividend. LH stock is up 1.39% in pre-market trading.

rttnews.com1 min
OCT 28
$LHMedAI 9/10

Labcorp’s (NYSE:LH) Q3 2026 sales beat estimates

Labcorp reported Q3 2026 revenue of $3.81B, exceeding estimates by 1.2% and growing 6.9% YoY. Adjusted EPS was $4.78, a 2.9% beat. The company raised full-year revenue and EPS guidance. Operating margin remained steady at 10.6%, while free cash flow margin improved to 10.8%. Organic revenue grew 5.5% YoY.

finance.yahoo.com2 min